The Correlations of Plasma Liver-Type Fatty Acid-Binding Protein with Amyloid-β and Tau Levels in Patients with Alzheimer’s Disease
The Correlations of Plasma Liver-Type Fatty Acid-Binding Protein with Amyloid-β and Tau Levels in Patients with Alzheimer’s Disease
复制标题
阿尔茨海默病患者血浆肝型脂肪酸结合蛋白与淀粉样蛋白 β 和 Tau 水平的相关性
DOI：
10.3233/jad-220126
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Yan-Jiang Wang
中科院分区：
文献类型：
--
作者：
Yuan Cheng;Jie-Ming Jian;Chen-Yang He;Jun-Rong Ren;Man-Yu Xu;Wang-Sheng Jin;Cheng-Rong Tan;Gui-Hua Zeng;Ying-Ying Shen;Dong-Wan Chen;Hui-Yun Li;Xu Yi;Yuan Zhang;Fan Zeng;Yan-Jiang Wang
脂代谢紊乱在阿尔茨海默病(AD)的发病机制中起着重要作用。为探讨肝型脂肪酸结合蛋白L在AD患者血浆和脑脊液中的水平变化及其与血浆和脑脊液中Aβ、tau水平的关系，对39例认知正常的AD患者和47例AD患者进行了横断面研究。用双抗体夹心酶联免疫吸附试验(ELISA)测定血浆FABP1值和脑脊液中Aβ、tau的含量。用单分子芯片检测AD患者血浆Aβ水平，发现AD组血浆FABP1水平显著升高(p=0.0109)。进一步分析发现FABP1与脑脊液总tau(t-tau)和磷酸化tau(p-tau)水平呈正相关。此外，血浆FABP1/Aβ42(AUC=0.6794，p=0.0071)和FABP1/t-tau(AUC=0.7168，p=0.0011)对AD有较好的诊断效果。当与其他常见的AD生物标志物包括血浆Aβ42、Aβ40和t-tau相结合时，β1/A FABP 1 42和FABP 1/t-tau均比单独使用这些生物标志物具有更好的诊断效果。在所有的AUC分析中，血浆FABP1/t-tau和Aβ42联合检测的诊断价值最高(AUC=0.8075，p<0.0001)，提示FABP1可能在AD的发病机制中起作用，值得进一步研究。
The dysregulation of lipid metabolism plays an important role in the pathogenesis of Alzheimer's disease (AD). Liver-type fatty acid-binding protein (L-FABP, also known as FABP1) is critical for fatty acid transport and may be involved in AD.To investigate whether the FABP1 level is altered in patients with AD, and its associations with levels of amyloid-β (Aβ) and tau in the plasma and cerebrospinal fluid (CSF).A cross-sectional study was conducted in a Chinese cohort consisting of 39 cognitively normal controls and 47 patients with AD. The levels of FABP1 in plasma, and Aβ and tau in CSF, were measured by enzyme-linked immunosorbent assay (ELISA). A single-molecule array (SIMOA) was used to detect plasma Aβ levels.The level of plasma FABP1 was significantly elevated in the AD group (p = 0.0109). Further analysis showed a positive correlation of FABP1 with CSF total tau (t-tau) and phosphorylated tau (p-tau) levels. Besides, plasma FABP1/Aβ42 (AUC = 0.6794, p = 0.0071) and FABP1/t-tau (AUC = 0.7168, p = 0.0011) showed fair diagnostic efficacy for AD. When combined with other common AD biomarkers including plasma Aβ42, Aβ40, and t-tau, both FABP1/Aβ42 and FABP1/t-tau showed better diagnostic efficacy than using these biomarkers alone. Among all AUC analyses, the combination of plasma FABP1/t-tau and Aβ42 had the highest diagnostic value (AUC = 0.8075, p < 0.0001).These findings indicate that FABP1 may play a role in AD pathogenesis and be worthy of further investigation in the future.